Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Conditions: RAS Mutation; Ras (Kras or Nras) Gene Mutation; Colorectal Cancer Recurrent; Pancreas Cancer; Lung Cancer; Melanoma; Refractory Cancer Interventions: Drug: Leflunomide; Drug: The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab Sponsors: N.N. Petrov National Medical Research Center of Oncology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials